Post-HTS case report and structural alert: Promiscuous 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one actives verified by ALARM NMR.

Despite its wide use, not every high-throughput screen (HTS) yields chemical matter suitable for drug development campaigns, and seldom are 'go/no-go' decisions in drug discovery described in detail. This case report describes the follow-up of a 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one active from a cell-free HTS to identify small-molecule inhibitors of Rtt109-catalyzed histone acetylation. While this compound and structural analogs inhibited Rtt109-catalyzed histone acetylation in vitro, further work on this series was halted after several risk mitigation strategies were performed. Compounds with this chemotype had a poor structure-activity relationship, exhibited poor selectivity among other histone acetyltransferases, and tested positive in a β-lactamase counter-screen for chemical aggregates. Furthermore, ALARM NMR demonstrated compounds with this chemotype grossly perturbed the conformation of the La protein. In retrospect, this chemotype was flagged as a 'frequent hitter' in an analysis of a large corporate screening deck, yet similar compounds have been published as screening actives or chemical probes versus unrelated biological targets. This report-including the decision-making process behind the 'no-go' decision-should be informative for groups engaged in post-HTS triage and highlight the importance of considering physicochemical properties in early drug discovery.

[1]  Uwe Karst,et al.  Analysis of glutathione adducts of patulin by means of liquid chromatography (HPLC) with biochemical detection (BCD) and electrospray ionization tandem mass spectrometry (ESI-MS/MS) , 2009, Analytical and bioanalytical chemistry.

[2]  A. Duranti,et al.  Identification of a bioactive impurity in a commercial sample of 6-methyl-2-p-tolylaminobenzo[d][1,3]oxazin-4-one (URB754). , 2007, Annali di chimica.

[3]  J. Baell,et al.  Chemistry: Chemical con artists foil drug discovery , 2014, Nature.

[4]  Q. You,et al.  Identification, Design and Bio-Evaluation of Novel Hsp90 Inhibitors by Ligand-Based Virtual Screening , 2013, PloS one.

[5]  Y. Pang,et al.  Chemical Structure of Retro-2, a Compound That Protects Cells against Ribosome-Inactivating Proteins , 2012, Scientific Reports.

[6]  Paul J Lewi,et al.  Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability. , 2005, Journal of medicinal chemistry.

[7]  V. L. Gein,et al.  Anti-inflammatory and analgesic activity of 5-aryl-4-acyl-1-heteryl-3-hydroxy-3-pyrrolin-2-ones , 2008, Pharmaceutical Chemistry Journal.

[8]  Renaldo Mendoza,et al.  ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens. , 2005, Journal of the American Chemical Society.

[9]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[10]  Erica M. Stec,et al.  A fluorescence-based thiol quantification assay for ultra-high-throughput screening for inhibitors of coenzyme A production. , 2008, Assay and drug development technologies.

[11]  Y. Li,et al.  The modus operandi of a DNA enzyme: enhancement of substrate basicity. , 1998, Chemistry & biology.

[12]  Ruili Huang,et al.  Fluorescence spectroscopic profiling of compound libraries. , 2008, Journal of medicinal chemistry.

[13]  Robert A Copeland,et al.  Mechanistic considerations in high-throughput screening. , 2003, Analytical biochemistry.

[14]  Takashi Matsumoto,et al.  Identification of novel chemical inhibitors for ubiquitin C-terminal hydrolase-L3 by virtual screening. , 2007, Bioorganic & medicinal chemistry.

[15]  E. Jacoby,et al.  Theoretical and Experimental Relationships between Percent Inhibition and IC50 Data Observed in High-Throughput Screening , 2013, Journal of biomolecular screening.

[16]  Brian K Shoichet,et al.  A detergent-based assay for the detection of promiscuous inhibitors , 2006, Nature Protocols.

[17]  A. Verkman,et al.  Small-Molecule Vasopressin-2 Receptor Antagonist Identified by a G-Protein Coupled Receptor “Pathway” Screen , 2007, Molecular Pharmacology.

[18]  L. Zhu,et al.  Histone acetyltransferase Rtt109 is required for Candida albicans pathogenesis , 2010, Proceedings of the National Academy of Sciences.

[19]  Patrick R. Griffin,et al.  PubChem promiscuity: a web resource for gathering compound promiscuity data from PubChem , 2012, Bioinform..

[20]  Heino Prinz,et al.  Hill coefficients, dose–response curves and allosteric mechanisms , 2010, Journal of chemical biology.

[21]  Jonathan B Baell,et al.  Screening-based translation of public research encounters painful problems. , 2015, ACS medicinal chemistry letters.

[22]  R. Fletterick,et al.  Discovery of Small Molecule Inhibitors of the Interaction of the Thyroid Hormone Receptor with Transcriptional Coregulators* , 2005, Journal of Biological Chemistry.

[23]  J. Bajorath,et al.  What is the Likelihood of an Active Compound to Be Promiscuous? Systematic Assessment of Compound Promiscuity on the Basis of PubChem Confirmatory Bioassay Data , 2013, The AAPS Journal.

[24]  Ronen Marmorstein,et al.  Fungal Rtt109 histone acetyltransferase is an unexpected structural homolog of metazoan p300/CBP , 2008, Nature Structural &Molecular Biology.

[25]  Brian K Shoichet,et al.  Interpreting steep dose-response curves in early inhibitor discovery. , 2006, Journal of medicinal chemistry.

[26]  Robert A Copeland,et al.  Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. , 2005, Methods of biochemical analysis.

[27]  R. Dayam,et al.  Substituted 2-pyrrolinone inhibitors of HIV-1 integrase. , 2007, Bioorganic & medicinal chemistry letters.

[28]  G. Rishton.  Nonleadlikeness and leadlikeness in biochemical screening. , 2003, Drug discovery today.

[29]  Stephen Gabriel,et al.  Metal impurities cause false positives in high-throughput screening campaigns. , 2013, ACS medicinal chemistry letters.

[30]  Philip Gribbon,et al.  Exemplification of the challenges associated with utilising fluorescence intensity based assays in discovery , 2010, Expert opinion on drug discovery.

[31]  J Willem M Nissink,et al.  Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold. , 2015, Journal of medicinal chemistry.

[32]  W. Patrick Walters,et al.  A guide to drug discovery: Designing screens: how to make your hits a hit , 2003, Nature Reviews Drug Discovery.

[33]  Junhong Han,et al.  Rtt109 Acetylates Histone H3 Lysine 56 and Functions in DNA Replication , 2007, Science.

[34]  Wei Xu,et al.  In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity. , 2014, Journal of molecular biology.

[35]  Peter Wipf,et al.  Profiling the NIH Small Molecule Repository for compounds that generate H2O2 by redox cycling in reducing environments. , 2010, Assay and drug development technologies.

[36]  Peter Wipf,et al.  Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. , 2008, Assay and drug development technologies.

[37]  Xuben Hou,et al.  Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening. , 2014, Journal of medicinal chemistry.

[38]  Anil Vasudevan,et al.  Abbott Physicochemical Tiering (APT)--a unified approach to HTS triage. , 2012, Bioorganic & medicinal chemistry.

[39]  D. Wolan,et al.  Self-assembling small molecules form nanofibrils that bind procaspase-3 to promote activation. , 2011, Journal of the American Chemical Society.

[40]  Alexander D. MacKerell,et al.  Targeting zymogen activation to control the matriptase-prostasin proteolytic cascade. , 2011, Journal of medicinal chemistry.

[41]  J H Zhang,et al.  Confirmation of primary active substances from high throughput screening of chemical and biological populations: a statistical approach and practical considerations. , 2000, Journal of combinatorial chemistry.

[42]  C. Ottmann,et al.  Identification and structure of small-molecule stabilizers of 14-3-3 protein-protein interactions. , 2010, Angewandte Chemie.

[43]  S. Yarmoluk,et al.  Identification of apoptosis signal-regulating kinase 1 (ASK1) inhibitors among the derivatives of benzothiazol-2-yl-3-hydroxy-5-phenyl-1,5-dihydro-pyrrol-2-one. , 2015, Bioorganic & medicinal chemistry.

[44]  Timothy L. Foley,et al.  4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide (ML267), a Potent Inhibitor of Bacterial Phosphopantetheinyl Transferase That Attenuates Secondary Metabolism and Thwarts Bacterial Growth , 2014, Journal of medicinal chemistry.

[45]  D. Bashford,et al.  Identification and Characterization of the First Small Molecule Inhibitor of MDMX* , 2010, The Journal of Biological Chemistry.

[46]  J. Baell.  Observations on screening-based research and some concerning trends in the literature. , 2010, Future medicinal chemistry.

[47]  Kim D Janda,et al.  Pharmacophore reassignment for induction of the immunosurveillance cytokine TRAIL. , 2014, Angewandte Chemie.

[48]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[49]  Jayme L. Dahlin,et al.  Histone-modifying enzymes, histone modifications and histone chaperones in nucleosome assembly: Lessons learned from Rtt109 histone acetyltransferases , 2015, Critical reviews in biochemistry and molecular biology.

[50]  D. Epps,et al.  A competitive fluorescence assay to measure the reactivity of compounds. , 2001, Analytical biochemistry.

[51]  Scott A. Busby,et al.  A Combined Ligand‐ and Structure‐Based Virtual Screening Protocol Identifies Submicromolar PPARγ Partial Agonists , 2011, ChemMedChem.

[52]  P. Thibault,et al.  Modulation of histone H3 lysine 56 acetylation as an antifungal therapeutic strategy , 2010, Nature Medicine.

[53]  Jayme L. Dahlin,et al.  Pneumocystis jirovecii Rtt109, a Novel Drug Target for Pneumocystis Pneumonia in Immunosuppressed Humans , 2014, Antimicrobial Agents and Chemotherapy.

[54]  Andreas Sewing,et al.  Fluorescence readouts in HTS: no gain without pain? , 2003, Drug discovery today.

[55]  Robert Nadon,et al.  Statistical practice in high-throughput screening data analysis , 2006, Nature Biotechnology.

[56]  G. Carta,et al.  Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds. , 2012, Journal of medicinal chemistry.

[57]  Jayme L. Dahlin,et al.  PAINS in the Assay: Chemical Mechanisms of Assay Interference and Promiscuous Enzymatic Inhibition Observed during a Sulfhydryl-Scavenging HTS , 2015, Journal of medicinal chemistry.

[58]  D. Huryn,et al.  The identification, characterization and optimization of small molecule probes of cysteine proteases: experiences of the Penn Center for Molecular Discovery with cathepsin B and cathepsin L. , 2009, Current topics in medicinal chemistry.

[59]  J. R. Merchant,et al.  Synthesis and reactions of some pyrrolidinediones. , 1971, Journal of medicinal chemistry.

[60]  Christopher P Austin,et al.  Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. , 2010, Journal of medicinal chemistry.

[61]  Petra Schneider,et al.  Scaffold Hopping by “Fuzzy” Pharmacophores and its Application to RNA Targets , 2007, Chembiochem : a European journal of chemical biology.

[62]  P. Wipf,et al.  A case study from the chemistry core of the Pittsburgh Molecular Library Screening Center: the Polo-like kinase polo-box domain (Plk1-PBD). , 2009, Current topics in medicinal chemistry.

[63]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[64]  J Willem M Nissink,et al.  Quantification of frequent-hitter behavior based on historical high-throughput screening data. , 2014, Future medicinal chemistry.

[65]  P. Kaufman,et al.  A small molecule inhibitor of fungal histone acetyltransferase Rtt109. , 2013, Bioorganic & medicinal chemistry letters.

[66]  Junhong Han,et al.  A role for Gcn5 in replication-coupled nucleosome assembly. , 2010, Molecular cell.

[67]  Jing Sun,et al.  Four-component reaction of cyclic amines, 2-aminobenzothiazole, aromatic aldehydes and acetylenedicarboxylate , 2013, Beilstein journal of organic chemistry.

[68]  Randy Hoffman,et al.  Overcoming compound interference in fluorescence polarization-based kinase assays using far-red tracers. , 2004, Assay and drug development technologies.

[69]  Christopher E. Berndsen,et al.  Assays for mechanistic investigations of protein/histone acetyltransferases. , 2005, Methods.

[70]  George Nikolakopoulos,et al.  PAINS: Relevance to Tool Compound Discovery and Fragment-Based Screening , 2013 .

[71]  Design, Synthesis, and Structure–Activity Relationship of a Novel Series of GluN2C-Selective Potentiators , 2014, Journal of medicinal chemistry.

[72]  Jeffrey R. Huth,et al.  Enhancement of chemical rules for predicting compound reactivity towards protein thiol groups , 2007, J. Comput. Aided Mol. Des..

[73]  D. Flower,et al.  Toward the Discovery of Vaccine Adjuvants: Coupling In Silico Screening and In Vitro Analysis of Antagonist Binding to Human and Mouse CCR4 Receptors , 2009, PloS one.

[74]  Guoqiang Dong,et al.  Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction. , 2012, Journal of medicinal chemistry.

[75]  Christopher P Austin,et al.  A high-throughput screen for aggregation-based inhibition in a large compound library. , 2007, Journal of medicinal chemistry.

[76]  É. Voronina,et al.  Synthesis and Antimicrobial Activity of 1,5-Diaryl-4-heteroyl-3-hydroxy-3-pyrrolin-2-ones , 2004, Pharmaceutical Chemistry Journal.

[77]  D. Flower,et al.  In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination , 2008, Proceedings of the National Academy of Sciences.

[78]  É. Voronina,et al.  Synthesis and pharmacological activity of 1-alkoxyaryl-5-aryl-4-acyl-3-hydroxy-3-pyrrolin-2-ones , 2011, Pharmaceutical Chemistry Journal.

[79]  Yanli Wang,et al.  A survey of across-target bioactivity results of small molecules in PubChem , 2009, Bioinform..

[80]  Jeremy R Kenseth,et al.  High-throughput characterization and quality control of small-molecule combinatorial libraries. , 2004, Current opinion in chemical biology.

[81]  J. Denu,et al.  Site-Specific Reactivity of Nonenzymatic Lysine Acetylation , 2015, ACS chemical biology.

[82]  Jayme L. Dahlin,et al.  A Cell-Free Fluorometric High-Throughput Screen for Inhibitors of Rtt109-Catalyzed Histone Acetylation , 2013, PloS one.

[83]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[84]  B. Maigret,et al.  Discovering new inhibitors of bacterial glucosamine-6P synthase (GlmS) by docking simulations. , 2007, Bioorganic & medicinal chemistry letters.

[85]  G. Rishton.  Reactive compounds and in vitro false positives in HTS , 1997 .

[86]  Jayme L. Dahlin,et al.  The essential roles of chemistry in high-throughput screening triage. , 2014, Future medicinal chemistry.

[87]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[88]  Jean M. Severin,et al.  Toxicological evaluation of thiol-reactive compounds identified using a la assay to detect reactive molecules by nuclear magnetic resonance. , 2007, Chemical research in toxicology.

[89]  Adam Yasgar,et al.  Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[90]  Paul A Johnston,et al.  Redox cycling compounds generate H2O2 in HTS buffers containing strong reducing reagents--real hits or promiscuous artifacts? , 2011, Current opinion in chemical biology.

[91]  Li Di,et al.  Stability Challenges in Drug Discovery , 2009, Chemistry & biodiversity.

[92]  Andrew C. Good,et al.  An Empirical Process for the Design of High-Throughput Screening Deck Filters , 2006, J. Chem. Inf. Model..

[93]  P. Bartlett,et al.  Synthesis and evaluation of inhibitors of bacterial D-alanine:D-alanine ligases. , 1996, Chemistry & biology.

[94]  Robert W. Bryant,et al.  Evaluation of Fluorescent Compound Interference in 4 Fluorescence Polarization Assays: 2 Kinases, 1 Protease, and 1 Phosphatase , 2003, Journal of biomolecular screening.